496 related articles for article (PubMed ID: 29913537)
1. Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.
Stufano F; Boscarino M; Bucciarelli P; Baronciani L; Maino A; Cozzi G; Peyvandi F
Semin Thromb Hemost; 2019 Feb; 45(1):36-42. PubMed ID: 29913537
[TBL] [Abstract][Full Text] [Related]
2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
3. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
4. von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease.
Sanders YV; Groeneveld D; Meijer K; Fijnvandraat K; Cnossen MH; van der Bom JG; Coppens M; de Meris J; Laros-van Gorkom BA; Mauser-Bunschoten EP; Leebeek FW; Eikenboom J;
Blood; 2015 May; 125(19):3006-13. PubMed ID: 25673639
[TBL] [Abstract][Full Text] [Related]
5. Von Willebrand factor propeptide makes it easy to identify the shorter Von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease.
Sztukowska M; Gallinaro L; Cattini MG; Pontara E; Sartorello F; Daidone V; Padrini R; Pagnan A; Casonato A
Br J Haematol; 2008 Oct; 143(1):107-14. PubMed ID: 18691167
[TBL] [Abstract][Full Text] [Related]
6. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study.
Pagliari MT; Rosendaal FR; Ahmadinejad M; Badiee Z; Baghaipour MR; Baronciani L; Benítez Hidalgo O; Bodó I; Budde U; Castaman G; Eshghi P; Goudemand J; Karimi M; Keikhaei B; Lassila R; Leebeek FWG; Lopez Fernandez MF; Mannucci PM; Marino R; Oldenburg J; Peake I; Santoro C; Schneppenheim R; Tiede A; Toogeh G; Tosetto A; Trossaert M; Yadegari H; Zetterberg EMK; Peyvandi F; Federici AB; Eikenboom J
J Thromb Haemost; 2022 May; 20(5):1106-1114. PubMed ID: 35092343
[TBL] [Abstract][Full Text] [Related]
7. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Lavin M; Brophy TM; Rawley O; O'Sullivan JM; Hayden PJ; Browne PV; Ryan K; O'Connell N; O'Donnell JS
J Thromb Haemost; 2016 Jun; 14(6):1200-5. PubMed ID: 26991062
[TBL] [Abstract][Full Text] [Related]
9. Acquired von Willebrand syndrome: von Willebrand factor propeptide to von Willebrand factor antigen ratio predicts remission status.
Lee A; Sinclair G; Valentine K; James P; Poon MC
Blood; 2014 Jul; 124(5):e1-3. PubMed ID: 24951428
[TBL] [Abstract][Full Text] [Related]
10. Genetic determinants of enhanced von Willebrand factor clearance from plasma.
Seidizadeh O; Baronciani L; Pagliari MT; Cozzi G; Colpani P; Cairo A; Siboni SM; Biguzzi E; Peyvandi F
J Thromb Haemost; 2023 May; 21(5):1112-1122. PubMed ID: 36754679
[TBL] [Abstract][Full Text] [Related]
11. Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease.
Casonato A; Daidone V; Padrini R
Semin Thromb Hemost; 2011 Jul; 37(5):456-63. PubMed ID: 22102187
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
[TBL] [Abstract][Full Text] [Related]
13. Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
Batsuli G; Zimowski KL; Carroll R; White MH; Woods GM; Meeks SL; Sidonio RF
J Cardiothorac Vasc Anesth; 2022 Mar; 36(3):724-727. PubMed ID: 33618961
[TBL] [Abstract][Full Text] [Related]
14. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
Haberichter SL; Castaman G; Budde U; Peake I; Goodeve A; Rodeghiero F; Federici AB; Batlle J; Meyer D; Mazurier C; Goudemand J; Eikenboom J; Schneppenheim R; Ingerslev J; Vorlova Z; Habart D; Holmberg L; Lethagen S; Pasi J; Hill FG; Montgomery RR
Blood; 2008 May; 111(10):4979-85. PubMed ID: 18344424
[TBL] [Abstract][Full Text] [Related]
15. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease.
Eikenboom J; Federici AB; Dirven RJ; Castaman G; Rodeghiero F; Budde U; Schneppenheim R; Batlle J; Canciani MT; Goudemand J; Peake I; Goodeve A;
Blood; 2013 Mar; 121(12):2336-9. PubMed ID: 23349392
[TBL] [Abstract][Full Text] [Related]
16. von Willebrand factor propeptide to antigen ratio identifies platelet activation and reduced von Willebrand factor survival phenotype in mice.
Jacobi PM; Kanaji S; Jakab D; Gehrand AL; Johnsen JM; Haberichter SL
J Thromb Haemost; 2018 Mar; 16(3):546-554. PubMed ID: 29285851
[TBL] [Abstract][Full Text] [Related]
17. Establishing a method for in vitro investigation of mechanical parameters causing acquired von Willebrand syndrome in ventricular assist devices.
Egger C; Maas J; Hufen T; Schmitz-Rode T; Steinseifer U
Artif Organs; 2013 Sep; 37(9):833-9. PubMed ID: 23834027
[TBL] [Abstract][Full Text] [Related]
18. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study.
Tiede A; Priesack J; Werwitzke S; Bohlmann K; Oortwijn B; Lenting P; Eisert R; Ganser A; Budde U
J Thromb Haemost; 2008 Apr; 6(4):569-76. PubMed ID: 18208537
[TBL] [Abstract][Full Text] [Related]
20. Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.
Haberichter SL; Balistreri M; Christopherson P; Morateck P; Gavazova S; Bellissimo DB; Manco-Johnson MJ; Gill JC; Montgomery RR
Blood; 2006 Nov; 108(10):3344-51. PubMed ID: 16835381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
